The benefit of the PD-(L)1 antagonists currently approved for the treatment of SCLC and NSCLC are limited to a small percentage of patients; our data suggest that combining them with Synthetic RNA viruses may improve outcomes in these patients. This evidence concerns the gene CD274 and non-small cell lung carcinoma.